# Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma

> **NCT02610556** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 130 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Cisplatin 2
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin 1
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT02610556
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2020-01
- **Final completion:** 2022-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2016-05-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610556, "Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02610556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*